International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Diagnostic Serum Markers for Pre–Eclampsia: An Overview

Mrs. Haripriya[1], Dr. Shreya Nigoshkar[2], Dr. Ketan Anant[3]

[1]PhD Scholar, Department of Biochemistry, Index Medical College, Indore, M.P, India
[2]Professor and Head, Department of Biochemistry, Index Medical College, Indore, M.P, India
[3]PG JR, Department of Microbiology, UPUMS, Saifai, Etawah

Abstract:
Pre-eclampsia, a hypertensive disorder of pregnancy, remains a major global health concern due to its potential for adverse maternal and fetal outcomes. Early and accurate diagnosis is crucial for effective management. Serum markers have emerged as valuable tools in this regard, offering insights into the pathophysiology and severity of pre-eclampsia. This comprehensive review explores the diagnostic utility of serum markers in pre-eclampsia. We examine the physiological basis and rationale for using specific markers, including serum uric acid, lactate dehydrogenase (LDH), alkaline phosphatase (ALP), 24-hour urine protein, and serum prolactin, among others. Additionally, we discuss the challenges and limitations associated with these markers, considering factors influencing marker levels and diagnostic interpretation. Serum markers, when integrated into clinical practice, enhance early diagnosis, risk stratification, and individualized care for pregnant individuals. They facilitate the identification of high-risk cases, prompt timely interventions, and reduce maternal and fetal complications associated with pre-eclampsia. Furthermore, clinical guidelines from authoritative bodies endorse the incorporation of serum markers in pre-eclampsia assessment. Serum markers represent a promising frontier in pre-eclampsia diagnosis, offering the potential to revolutionize prenatal care. While challenges exist, ongoing research, standardization efforts, and larger-scale studies will further refine the clinical utility of serum markers. Their integration aligns with established guidelines and holds the promise of improving maternal and fetal outcomes, making a significant impact on global maternal healthcare.

Keywords: Pre-eclampsia, Serum biomarkers, Maternal-fetal outcomes, Uric acid, Lactate dehydrogenase (LDH), Alkaline phosphatase (ALP), 24-hour urine protein, Prolactin

1. Introduction

Pre-eclampsia is a complex and potentially life-threatening condition that occurs during pregnancy, typically in the second half of gestation. It is characterized by new-onset hypertension (elevated blood pressure) and significant proteinuria (excess protein in the urine). [1]While pre-eclampsia primarily affects the mother, it also poses significant risks to the developing fetus. This condition is a leading cause of maternal and perinatal morbidity and mortality worldwide.[2]

The clinical significance of pre-eclampsia in pregnancy cannot be overstated. It is associated with a range of complications, including but not limited to:

- Hypertensive Emergencies: Pre-eclampsia can rapidly progress to severe hypertension, leading to potentially life-threatening conditions such as eclampsia (seizures) and stroke.[3]

- Organ Dysfunction: It can affect various organ systems, including the liver, kidneys, brain, and blood clotting mechanisms, resulting in organ damage.
- Fetal Growth Restriction: Pre-eclampsia can impair placental function, leading to poor fetal growth, low birth weight, and premature birth.
- Placental Abruption: In severe cases, it can increase the risk of placental abruption, where the placenta prematurely separates from the uterine wall, which can be life-threatening for both the mother and the baby.

Given these potential complications, the early and accurate diagnosis of pre-eclampsia is of paramount importance. Timely identification of pre-eclampsia allows healthcare providers to initiate appropriate interventions, closely monitor maternal and fetal well-being, and make informed decisions regarding the timing of delivery. One avenue that holds promise for improving the diagnosis of pre-eclampsia is the use of serum markers, which are specific molecules found in the blood. These serum markers have the potential to serve as diagnostic tools to aid in the early identification of pre-eclampsia and the stratification of its severity. By analyzing specific serum markers, healthcare providers may be able to distinguish pre-eclampsia from other pregnancy-related conditions and assess the risk of complications.[4]

The structure of this article is designed to comprehensively explore the topic of diagnostic serum markers for pre-eclampsia. In the following sections, we will delve into the various serum markers that have been studied for this purpose, evaluating their diagnostic accuracy, clinical utility, and potential challenges. We will also discuss future research directions and the clinical implications of incorporating serum markers into the diagnostic algorithm for pre-eclampsia. This review aims to provide valuable insights into the role of serum markers in improving the early diagnosis and management of pre-eclampsia, ultimately contributing to better maternal and fetal outcomes.

2. Pre-eclampsia: Clinical Features and Challenges

2.1 Clinical Presentation and Progression of Pre-eclampsia:

Pre-eclampsia is a multisystem disorder that primarily affects pregnant individuals after 20 weeks of gestation, although it can sometimes occur earlier in pregnancy. It is characterized by a wide range of clinical features, and its presentation can vary in severity from mild to severe. [5]The clinical features and progression of pre-eclampsia includes:

- Hypertension: Elevated blood pressure (hypertension) is a hallmark sign of pre-eclampsia. A systolic blood pressure of 140 mm Hg or higher and/or a diastolic blood pressure of 90 mm Hg or higher, on two separate occasions at least 4 hours apart, is diagnostic. However, some individuals with pre-eclampsia may not initially exhibit markedly elevated blood pressure.
- Proteinuria: Proteinuria, or the presence of excess protein in the urine, is another key feature. In pre-eclampsia, proteinuria is typically defined as ≥300 milligrams of protein in a 24-hour urine collection or ≥1+ on a dipstick test. However, proteinuria may not always be present, especially in cases of early or mild pre-eclampsia.
- Edema: Edema, or swelling, is a common symptom, but it is not specific to pre-eclampsia and can occur in healthy pregnancies as well. Edema often presents in the hands, face, and lower extremities.
- Headache: Some individuals with pre-eclampsia may experience persistent, severe headaches, often in the frontal region.
- Visual Disturbances: Vision changes, such as blurred vision or seeing flashing lights, can occur due to the impact of pre-eclampsia on the visual system.

- Upper Abdominal Pain: Pain or discomfort in the upper right quadrant of the abdomen, beneath the ribcage, may signal liver involvement in severe pre-eclampsia.
- Nausea and Vomiting: Gastrointestinal symptoms, including nausea and vomiting, can accompany pre-eclampsia, particularly in severe cases.

2.2 Challenges in Diagnosing Pre-eclampsia Based Solely on Clinical Symptoms:

Diagnosing pre-eclampsia based solely on clinical symptoms poses several challenges. Many of the symptoms of pre-eclampsia, such as headache and edema, are non-specific and can mimic common discomforts of pregnancy. This can make it challenging to differentiate pre-eclampsia from normal pregnancy-related symptoms. Pre-eclampsia can present with a wide range of clinical features, and its severity can vary. Some individuals may have mild symptoms, while others may rapidly progress to severe complications. Pre-eclampsia does not always follow a typical pattern. In some cases, individuals may develop severe hypertension or organ dysfunction without obvious proteinuria.[6]

2.3 Importance of Early Detection to Prevent Maternal and Fetal Complications:

Early detection and diagnosis of pre-eclampsia are critical for several reasons:

- Risk Mitigation: Early diagnosis allows for timely initiation of appropriate medical interventions and management strategies, reducing the risk of severe complications for both the mother and the fetus.
- Monitoring: Once diagnosed, individuals with pre-eclampsia require close monitoring of blood pressure, organ function, and fetal well-being to assess the need for delivery or other medical interventions.
- Maternal Health: Pre-eclampsia can lead to maternal complications, including seizures (eclampsia), stroke, liver dysfunction, and kidney injury. Early detection and management can help prevent these life-threatening events.
- Fetal Health: Pre-eclampsia is associated with fetal growth restriction, preterm birth, and other adverse outcomes. Early diagnosis allows for interventions to optimize fetal growth and well-being.

3. Biomarkers in Pre-eclampsia

Biomarkers are measurable biological molecules found in tissues, blood, urine, or other body fluids that provide information about a biological process, condition, or disease. These molecules can be proteins, nucleic acids (like DNA and RNA), metabolites, or other substances. Biomarkers serve several critical roles in healthcare, including disease diagnosis, prognosis, prediction of treatment response, and monitoring disease progression.[7]

In the context of disease diagnosis, biomarkers are invaluable because they allow healthcare providers to:

- Identify the presence of a disease or condition.
- Distinguish between different diseases or disease subtypes.
- Assess the severity or stage of a disease.
- Predict the likelihood of disease progression or recurrence.

Biomarkers can be particularly important in diseases like pre-eclampsia, where early detection and intervention are crucial for optimal patient outcomes.

Serum markers, also referred to as blood-based biomarkers, are biomolecules present in the blood that can provide information about the presence and characteristics of a disease. In the context of pre-eclampsia, serum markers are substances that are measured in a blood sample and are potentially indicative of the

condition. These markers are particularly useful because blood samples are routinely collected during prenatal care, making them readily accessible for diagnostic purposes.[8]

Serum markers in pre-eclampsia are valuable because they can aid in Early diagnosis of pre-eclampsia, even before clinical symptoms manifest, Stratification of the risk of severe pre-eclampsia, Monitoring disease progression and response to treatment and in differentiating pre-eclampsia from other hypertensive disorders of pregnancy.

4. Overview of Various Biomarkers Studied for Pre-eclampsia Diagnosis:

Several biomarkers have been investigated for their potential role in diagnosing pre-eclampsia. These biomarkers often reflect different aspects of the pathophysiological processes associated with the condition. Biomarkers, particularly serum markers, play a crucial role in diagnosing pre-eclampsia by providing objective and quantifiable information about the condition. These markers have the potential to enhance early detection, risk assessment, and monitoring of pre-eclampsia, ultimately improving maternal and fetal outcomes.

Some commonly studied serum markers for pre-eclampsia include:

- Serum Uric Acid: Elevated uric acid levels have been associated with endothelial dysfunction, a hallmark feature of pre-eclampsia. [9]
- Lactate Dehydrogenase (LDH): Increased LDH levels may indicate tissue damage and organ dysfunction, which can occur in severe pre-eclampsia.
- Alkaline Phosphatase (ALP): ALP is an enzyme found in the liver and bones, and elevated levels may suggest liver involvement in pre-eclampsia.
- 24-Hour Urine Protein: Proteinuria is a classic feature of pre-eclampsia, and measuring the amount of protein in a 24-hour urine collection is a diagnostic criterion.
- Serum Prolactin: Serum prolactin levels may be altered in pre-eclampsia, although their utility as a standalone marker is still being explored.
- Other biomarkers, such as angiogenic factors (e.g., sFlt-1 and PlGF) and inflammatory markers, have also shown promise in pre-eclampsia diagnosis and risk stratification.

5. Serum Markers with Diagnostic Potential for Pre-eclampsia Diagnosis

These serum markers play crucial roles in diagnosing and assessing pre-eclampsia. They offer insights into various aspects of the condition, including endothelial dysfunction, tissue damage, renal impairment, and liver dysfunction. While they individually contribute to the diagnostic process, they are often used in combination to enhance accuracy and assist in early detection and risk stratification of pre-eclampsia cases.[10]

5.1 Serum Uric Acid:

Physiological Basis: Elevated serum uric acid levels in pre-eclampsia are linked to endothelial dysfunction. Impaired endothelial function reduces the clearance of uric acid, leading to higher levels in the bloodstream.

Rationale: Serum uric acid is a readily available and cost-effective marker. It is a well-established marker for pre-eclampsia, especially in combination with other clinical findings.[11]

5.2 Lactate Dehydrogenase (LDH):

Physiological Basis: LDH is an enzyme found in various tissues, including red blood cells. Elevated LDH levels can indicate tissue damage and hemolysis, both of which are associated with severe pre-eclampsia.

Rationale: LDH serves as an indicator of organ dysfunction and hemolysis, which are common in severe pre-eclampsia cases. Monitoring LDH levels can aid in assessing disease severity.

5.3 Alkaline Phosphatase (ALP):

Physiological Basis: ALP is an enzyme present in the liver and bones. Elevated ALP levels may indicate liver involvement, a complication often seen in severe pre-eclampsia.

Rationale: Increased ALP levels can help identify liver dysfunction, which is a component of the HELLP syndrome, a severe form of pre-eclampsia. Monitoring ALP levels aids in evaluating the extent of liver involvement.[12]

5.4 24-Hour Urine Protein:

Physiological Basis: Proteinuria, or the presence of excess protein in the urine, is a hallmark of pre-eclampsia. It results from compromised glomerular filtration due to endothelial dysfunction in the kidneys.

Rationale: Measuring proteinuria through a 24-hour urine collection is a well-established diagnostic criterion for pre-eclampsia. It directly reflects renal involvement and is a key indicator for diagnosis and assessing severity.[13]

5.5 Serum Prolactin:

Physiological Basis: Altered serum prolactin levels in pre-eclampsia are not fully understood but may involve interactions between the placenta and pituitary gland.

Rationale: Serum prolactin has shown potential as a pre-eclampsia marker; however, its use as a standalone diagnostic tool is still under investigation. Further research is needed to clarify its role.[14]

5.6 Other Serum Markers (As Applicable):

Additional markers, such as angiogenic factors (e.g., sFlt-1 and PlGF) and inflammatory markers, have been explored for their diagnostic potential in pre-eclampsia. These markers are associated with the vascular dysfunction and inflammation contributing to the condition.[15]

6. Challenges and Limitations

While serum markers offer valuable insights into the diagnosis of pre-eclampsia, they come with several challenges and limitations that must be considered:

1. Non-Specificity of Markers: Many serum markers, such as elevated uric acid, LDH, or ALP, are not specific to pre-eclampsia. These markers can also be elevated in other medical conditions, making it challenging to differentiate pre-eclampsia from other disorders based solely on serum marker levels. Non-specific markers can lead to false-positive results and unnecessary diagnostic workup or interventions in pregnant individuals who do not have pre-eclampsia
2. Variability in Marker Levels: Serum marker levels can vary among individuals and across different stages of pregnancy. Normal physiological changes during pregnancy, such as increased blood volume and altered renal function, can influence marker levels. Variability in marker levels may lead to uncertainty in diagnosis, especially when relying on single-point measurements. Reference ranges and cutoff values must consider gestational age and individual variations.
3. Limited Predictive Value: While serum markers can aid in the diagnosis of pre-eclampsia, they may have limited predictive value for the onset or progression of the condition. Some markers may become abnormal only after clinical symptoms appear. The inability to predict pre-eclampsia before symptoms manifest limits the potential for early intervention and prevention.
4. Multiple Marker Combinations: Effective pre-eclampsia diagnosis often requires the use of multiple serum markers in combination. Determining the optimal combination and interpreting results can be

complex.The use of multiple markers increases the complexity of diagnostic algorithms and may not be feasible in resource-limited settings.

5. Interference and Confounders: Various factors, such as medications, comorbidities, or dietary factors, can influence serum marker levels. For example, certain medications may affect uric acid levels, leading to misinterpretation. The presence of confounding factors can complicate the interpretation of marker results, requiring careful consideration of potential interferences.
6. Evolving Research: Research on serum markers for pre-eclampsia is ongoing, with new markers and diagnostic approaches continually emerging. The rapidly evolving landscape of pre-eclampsia diagnostics means that clinical practice guidelines and reference values may need frequent updates to reflect the latest evidence.
7. Lack of Standalone Diagnostic Markers: No single serum marker has been identified as a definitive standalone diagnostic tool for pre-eclampsia.The absence of a single gold standard marker means that a combination of markers or clinical criteria is often required for diagnosis, which can be complex to implement.

7. Future Directions and Research Gaps

Future research should focus on the discovery and validation of novel biomarkers specifically associated with pre-eclampsia. Identifying markers that are highly specific to the condition could enhance diagnostic accuracy. Research should aim to identify biomarkers that have predictive value for pre-eclampsia, allowing for early risk assessment and intervention before clinical symptoms develop. Developing comprehensive marker panels and diagnostic algorithms that integrate multiple serum markers, clinical parameters, and gestational age for pre-eclampsia diagnosis could improve accuracy and risk stratification. Longitudinal studies that track changes in serum marker levels throughout pregnancy in individuals who develop pre-eclampsia can provide valuable insights into the dynamic nature of these markers. Investigating the influence of potential confounding factors, such as medications, comorbidities, and dietary factors, on serum marker levels is crucial for refining interpretation guidelines. Efforts should be made to standardize assay methodologies and establish reference ranges for serum markers across different gestational ages and populations to ensure consistent and reliable results. Research should address the challenges of implementing serum markers into routine clinical practice, considering cost-effectiveness, accessibility, and feasibility in various healthcare settings.

8. Conclusion:

The utilization of diagnostic serum markers for pre-eclampsia offers substantial potential to revolutionize the landscape of prenatal care. The key findings and insights regarding these markers underscore their pivotal role in early diagnosis and the subsequent improvement of maternal and fetal outcomes. Serum markers such as uric acid, lactate dehydrogenase (LDH), alkaline phosphatase (ALP), 24-hour urine protein, and others provide valuable windows into the complex pathophysiology of pre-eclampsia. Serum markers allow for the detection of pre-eclampsia in its earliest stages, often before clinical symptoms become evident. This early diagnosis is invaluable in implementing timely interventions. By distinguishing between mild and severe pre-eclampsia and identifying high-risk individuals, serum markers enable healthcare providers to tailor care plans, thereby optimizing maternal and fetal well-being. Early identification through serum markers prompts preventive measures, such as lifestyle modifications and medication regimens, to mitigate the progression of pre-eclampsia and its associated complications.

Serum markers facilitate the delivery of individualized care plans, taking into account the severity and progression of pre-eclampsia. This personalized approach optimizes healthcare resource allocation. Ultimately, the use of serum markers can lead to a significant reduction in maternal and fetal complications associated with pre-eclampsia, including eclampsia, stroke, preterm birth, and growth restriction.

References:

1. Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019 May;15(5):275-289. doi: 10.1038/s41581-019-0119-6. Erratum in: Nat Rev Nephrol. 2019 Jun;15(6):386. PMID: 30792480; PMCID: PMC6472952.
2. Magley M, Hinson MR. Eclampsia. [Updated 2023 Jan 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554392/
3. Varon, J., Marik, P.E. Clinical review: The management of hypertensive crises. *Crit Care* **7**, 374 (2003). https://doi.org/10.1186/cc2351.
4. Fox R, Kitt J, Leeson P, Aye CYL, Lewandowski AJ. Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring. J Clin Med. 2019 Oct 4;8(10):1625. doi: 10.3390/jcm8101625. PMID: 31590294; PMCID: PMC6832549.
5. Lai J, Syngelaki A, Nicolaides KH, von Dadelszen P, Magee LA. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes. Am J Obstet Gynecol. 2021 May;224(5):518.e1-518.e11. doi: 10.1016/j.ajog.2020.11.004. Epub 2020 Nov 6. PMID: 33166504.
6. Gupte S, Wagh G. Preeclampsia-eclampsia. J Obstet Gynaecol India. 2014 Feb;64(1):4-13. doi: 10.1007/s13224-014-0502-y. Epub 2014 Jan 31. PMID: 24587599; PMCID: PMC3931898.
7. Sarhadi VK, Armengol G. Molecular Biomarkers in Cancer. Biomolecules. 2022 Jul 23;12(8):1021. doi: 10.3390/biom12081021. PMID: 35892331; PMCID: PMC9331210.
8. Nalejska E, Mączyńska E, Lewandowska MA. Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther. 2014 Jun;18(3):273-84. doi: 10.1007/s40291-013-0077-9. PMID: 24385403; PMCID: PMC4031398.
9. Shin SY, Centenera MM, Hodgson JT, Nguyen EV, Butler LM, Daly RJ, Nguyen LK. A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancer. Front Mol Biosci. 2023 Jan 19;10:1094321. doi: 10.3389/fmolb.2023.1094321. PMID: 36743211; PMCID: PMC9892654.
10. Bainbridge SA, Roberts JM. Uric acid as a pathogenic factor in preeclampsia. Placenta. 2008 Mar;29 Suppl A(Suppl A):S67-72. doi: 10.1016/j.placenta.2007.11.001. Epub 2008 Feb 21. PMID: 18093648; PMCID: PMC3319018.
11. Bellos I, Pergialiotis V, Loutradis D, Daskalakis G. The prognostic role of serum uric acid levels in preeclampsia: A meta-analysis. J Clin Hypertens (Greenwich). 2020 May;22(5):826-834. doi: 10.1111/jch.13865. Epub 2020 Apr 27. PMID: 32338457; PMCID: PMC8030030.
12. Hammoud GM, Ibdah JA. Preeclampsia-induced Liver Dysfunction, HELLP syndrome, and acute fatty liver of pregnancy. Clin Liver Dis (Hoboken). 2014 Sep 26;4(3):69-73. doi: 10.1002/cld.409. PMID: 30992924; PMCID: PMC6448736.

13. Abdelazim IA, Amer OO, Shikanova S, Karimova B. Protein/creatinine ratio versus 24-hours urine protein in preeclampsia. Ginekol Pol. 2022;93(12):975-979. doi: 10.5603/GP.a2021.0233. Epub 2022 Feb 14. PMID: 35156696.
14. Al-Chalabi M, Bass AN, Alsalman I. Physiology, Prolactin. [Updated 2023 Jul 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507829/
15. Shahid R, Bari MF, Hussain M. Serum biomarkers for the prediction and diagnosis of preeclampsia: A meta-analysis. J Taibah Univ Med Sci. 2021 Aug 11;17(1):14-27. doi: 10.1016/j.jtumed.2021.07.003. PMID: 35140561; PMCID: PMC8802864.